普健生物（武汉）科技有限公司（AtaGenix）
Rituximab ( 利妥昔单抗 )
- 1
- 2
Related Products
- Recombinant Human MS4A1 protein ,N- His Tag
- Recombinant Human CD20 protein ,N- His Tag
- Recombinant Human MS4A1 protein ,N- His Tag
- Recombinant Human MS4A1 protein
- 产品信息
- 如何订购
- 说明书
货号（Catalog No.）icon
ATAD00089
通用名INNicon
Rituximab
纯度(Purity)icon
>95%
电泳图（SDS-PAGE image）icon
浓度( Concentration)icon
1mg/ml
Formulationicon
PBS buffer PH7.5
Sourceicon
CHO cells
内毒素(Endotoxin level)icon
Please contact with the lab for this information.
生物活性icon
产品描述(Description)
Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences 6, Label. It was originally approved by the U.S. FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) 8, however, has now been approved for a variety of conditions Label. On November 28, 2018, the US FDA approved Truxima, the first biosimilar to Rituxan (Rituximab) 7.Rituximab is a monoclonal antibody that targets the CD20 antigen, which is expressed on the surface of pre-B and mature B-lymphocytes 1, 2, 3, Label. After binding to CD20, rituximab mediates B-cell lysis (or breakdown). The possible mechanisms of cell lysis include complement dependent cytotoxicity (CDC) and antibody dependent cell-mediated cytotoxicity (ADCC) Label.
别名(Alternative names)
IDEC-C2B8
靶点;物种(Specificity target name;species)
MS4A1[Homo sapiens]
活性研究（体外/体内研究）(Activity in vitro)
Complement-dependent cytotoxicity(CDC), complement-dependent cellular cytotoxicity(CDCC), antibody-dependent cytotoxicity (ADCC) as well as the induction of apoptosis have been claimed to be responsible for the efficacy of rituximab. Rituximab can induce death of malignant B cell lines in vitro. The strength of this effect varies considerably between target cell lines. Changes that have been identified in response to rituximab in vitro include inhibition of p38 mitogen-activated protein kinase, NF-κB, extracellular signal-regulated kinase 1/2 (ERK 1/2) and AKT antiapoptotic survival pathways. Rituximab is highly efficient at mediating CMC(complement dependent cytotoxicity) of various B cell lines as well as fresh malignant B cell samples. CD20-binding capacity of rituximab is dose-dependent.
种类(Species)
Humanized
受体鉴定(Receptor identification)
IgG1-kappa
活性验证（图片、数据）(Bioactivity)icon
化学信息icon
分子量(MV)
148000.00 Da
CAS
174722-31-7
存储条件(Storage)
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Store at +4°C short term (1-2 weeks).
Store at -20 °C 12 months.
Store at -80°C long term.
Store at +4°C short term (1-2 weeks).
Store at -20 °C 12 months.
Store at -80°C long term.
Noteicon
For research use only .
1搜索商品：关键字搜索；分类导航搜索；产品联系：手机/微信同号：15972188750，座机：027-65279366（推荐 ！）
2产品选购：确定好产品信息与规格，向产品客服询问底价
3提交订单：向客服提交收货人信息，选择送货方式，支付方式，发票信息
4产品发货：发票随产品一起发送，耐心等待收货即可
质量保证：
所售产品均经过严格的质量检验，确保所供产品的技术指标与生产厂家的目录、说明书、质检报告上的描述一致，请放心选购。
质量与免责说明：
买方验收产品时，如发现产品短缺、不匹配、包装破损等情况，请保持产品原包装状态，并在收货七个工作日内，以书面方式向我司提出异议。逾期未提出异议视为合格。
买方保管产品时，应按照产品标签、说明书所示保管条件保存，如系保管不当导致产品质量问题，恕不受理。
买方使用产品时。如发现产品质量问题，应在使用初期提出，而非在使用完或快使用完时提出，以备我司回收产品，确认产品质量。如确属质量问题，我司负责调换或退货。发生索赔事宜，我司将在产品价格额度范围内酌情赔偿，恕不受理超出产品本身价值之部分。自收货之日起，超过三个月未反映产品问题，恕不退换。
我司所提供的产品仅限于专业人士的科学研究使用，不得用于临床诊断或者治疗，若有单位或者个人擅自改变我司产品用途，我司不承担任何责任。
- 服务咨询电话：027-87001869
- 产品咨询电话：027-65279366
- 邮箱：Info@atagenix.com[商务咨询] Sales@atagenix.com[订单咨询]
- 地址：武汉东湖新技术开发区神墩四路 666 号C栋
关注“普健生物”
微信公众号
普健生物（武汉）科技有限公司（AtaGenix） 鄂ICP备15005566号-1
Copyright © 2024 Lawyer Theme All Rights Reserved
Copyright © 2024 Lawyer Theme All Rights Reserved